Compare Eli Lilly And Co (LLY) vs Mattel Inc (MAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Mattel Inc — how do they compare? Eli Lilly And Co trades at $1,173.02 (market cap $1.04T), while Mattel Inc trades at $16.67 (market cap $4.74B). The key difference: Eli Lilly And Co is far larger — about 219.4× Mattel Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Mattel Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Mattel Inc for 97 Days on average.
| LLY | MAT | |
|---|---|---|
Market Cap | $1.04T | $4.74B |
Volume | 3,064,878 | 11,809,722 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $22.16 |
52-Week Low | $799.57 | $12.66 |
Typical Hold Time | 93 Days | 97 Days |
Enterprise Value | $1.09T | $6.96B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Mattel (MAT) trades at $17.12, up 4.58% amid takeover speculation from Authentic Brands Group. The stock shows bullish technical signals with strong moving average support, though RSI levels indicate overbought conditions. Fundamentally, the company maintains solid profitability with 7.78% net margins and 20.5% ROE, though recent earnings have been mixed with two misses in the last three quarters. Leadership transition is underway with Roger Lynch replacing Ynon Kreiz as CEO.
The takeover interest creates near-term upside potential, but execution risks remain under new leadership. Analyst consensus is bullish with 53% buy ratings and $15 price target, though current price exceeds target. Key risks include Barbie sales deterioration, integration challenges for new CEO, and declining operating cash flow from $870M in 2023 to $593M in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
